In Brief: Ethex' generic disopyramide
Ethex' generic disopyramide: KV Pharmaceuticals subsidiary announces the availability of disopyramide phosphate 150 mg ER capsules Feb. 2. The extended-release anti-arrhythmia drug has been validated under terms of a June 1993 consent decree that followed a seizure action. FDA says most KV products seized have gone through the review process and expects more products to be made available. The Ethex drug is the only AB-rated generic alternative to Searle's Norpace...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth